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with DFI are Medicare-eligible, and hospitals are motivated to
decrease costs without altering patient outcomes. A large, mul-
ticenter, randomized, double-blind trial (SIDESTEP) comparing
ertapenem (1g QD) and piperacillin/tazobactam (3.375g QID)
found equivalent efﬁcacy in the treatment of DFI. METHODS:
Individuals enrolled in SIDESTEP, treated entirely as inpatients,
and clinically evaluable at ﬁnal assessment (10 days after com-
pleting antibiotic therapy; n = 99) were included. Cost per dose
was calculated from a) average actual hospital acquisition
price/dose (IMS Health, National Sales Perspectives) for 2005 in
U.S. dollars for ertapenem ($40.52) or piperacillin/tazobactam
($13.58); b) average U.S. wage and beneﬁts for labor, based a
review of 10 time-and-motion studies of intravenous antibiotic
drug preparation and administration ($3.03); and c) consumable
supplies, using a 40% discount off manufacturer list price in the
2005 Redbook ($2.52). For each patient, actual doses (either
ertapenem or piperacillin/tazobactam) was multiplied by total
cost per dose (ertapenem = $45.23; piperacillin/tazobactam =
$19.13). RESULTS: No differences with respect to demograph-
ics, mean length of treatment or wound severity were 
noted (intravenous therapy days: ertapenem = 6.6; piperacillin/
tazobactam = 6.4); (wound severity: ertapenem = 29%;
piperacillin/tazobactam = 26% severe). Differences were signiﬁ-
cant with respect to mean doses of active drug (ertapenem = 7.6;
piperacillin/tazobactam = 25.7; p < 0.0001) and costs (ertapenem
= $352.11; piperacillin/tazobactam = $491.20; p = 0.018). The
$139.10 difference between groups accounts for approximately
3% of total hospital DRG reimbursements for Medicare
patients. CONCLUSIONS: Once-daily dosing of ertapenem
offers the advantage of less cost to hospitals, compared to QID
dosing for piperacillin/tazobactam, without compromising 
efﬁcacy or safety.
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OBJECTIVES: Ribavirin-induced anemia is a common adverse
effect of chronic hepatitis C treatment. Pilot studies have shown
that the use of epoetin has decreased the need for ribavirin dose
reduction or discontinuation. Our goal was to calculate the
incremental cost-effectiveness of using epoetin to treat ribavirin-
induced anemia, per ribavirin dose reduction or discontinuation
averted. Our secondary aim was to calculate the incremental cost
of hepatitis C treatment, comparing those who developed anemia
to those who did not, using each of two strategies: ribavirin dose
reduction/discontinuation or epoetin. METHODS: Using esti-
mates from the literature and decision-analytic techniques, we
modeled treatment patterns and estimated the cost of managing
ribavirin-induced anemia. One-way sensitivity analyses were
used to address uncertainty. RESULTS: Clinically signiﬁcant
anemia, deﬁned as a 2 g/dL or greater reduction in hemoglobin,
developed in approximately 72% of patients in observational
studies. The cost-effectiveness of using epoetin to treat ribavirin-
induced anemia ranged from $39,579 (severe anemia, genotype-
2/3) to $52,200 (moderate anemia, genotype-1), per ribavirin
dose reduction/discontinuation averted. The incremental cost of
treating hepatitis C, comparing patients with anemia to those
without, using ribavirin dose reduction/discontinuation saved
$2742 (genotype-1) and $323 (genotype-2/3); when using
epoetin; the additional cost was $2075 and $5501, for genotype-
1 and genotype-2/3 patients, respectively. CONCLUSIONS: The
incremental cost of treating ribavirin—induced anemia is
minimal, and varies with the probability of developing anemia.
However, once anemia has developed, the cost of using epoetin
per ribavirin dose modiﬁcation averted is substantial; and varies
with the probability of response to epoetin. These ﬁndings
suggest that additional studies are warranted that will deﬁne
both genotype-speciﬁc strategies to treat ribavirin-induced
anemia and the optimal use of epoeitin as adjunctive therapy in
patients with chronic hepatitis C.
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OBJECTIVES: Military recruits undergo screening for LTBI at
accession with TST. The low speciﬁcity of TST results in false
positives and unnecessary LTBI treatment. A highly speciﬁc
whole blood assay for the diagnosis of LTBI exists (QFT—GIT,
Cellestis) pending FDA approval. Unlike TST, administration of
QFT-GIT at application to military service is feasible and would
permit exclusion of LTBI positives. We investigated the potential
cost savings of implementing universal application QFT-GIT
testing with or without conﬁrmatory accession QFT-GIT testing
and treatment, to determine whether QFT-GIT testing costs are
offset by reduced LTBI treatment costs. METHODS: A decision
tree was constructed to model the direct costs of TST testing and
LTBI treatment of accessions versus the costs of alternative poli-
cies of QFT-GIT applicant testing with or without conﬁrmatory
accession QFT-GIT testing and treatment. Average LTBI treat-
ment costs per positive test were expressed as a ratio to the cost
of QFT-GIT testing (treatment: cost ratio). Costs of administer-
ing and reading a TST were assumed to be zero, and QFT-GIT
costs were normalized per accession. RESULTS: Applicant QFT-
GIT testing was economical over TST above a treatment: cost
ratio of 52 :1, while conﬁrmatory QFT-GIT testing was eco-
nomical over TST above a treatment:cost ratio of 108 :1. In 
two-way sensitivity analysis, threshold ratios decreased with
increasing LTBI prevalence and increasing probability of acces-
sion and were relatively insensitive to uncertainty in test char-
acteristics. CONCLUSIONS: Application QFT-GIT results in
fewer LTBI positive accessions and should be implemented if
cost-beneﬁcial. Quantiﬁcation of the direct costs of LTBI treat-
ment are needed to determine the maximum cost of QFT-GIT
testing to economically implement this policy, and whether
improved sensitivity can be economically achieved with conﬁr-
matory QFT-GIT testing.
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OBJECTIVES: Streptococcus pneumoniae is a leading bacterial
cause of septicaemia, meningitis, pneumonia and otitis media
and may cause severe sequelae or death. A 7-valent conjugate
pneumococcal vaccine (Prevenar) has proved effective in pre-
venting otitis and invasive pneumococcal disease (IPD) in chil-
dren. A reduction in IPD has also been observed in some adult
age groups, possibly due to herd immunity. The aim of this study
was to explore the cost-effectiveness of vaccination of infants in
Norway. METHODS: The study was based on a Markov-model
